生物追踪器Meddevicetracker 2025年第二季度展望报告（英）

Brought to you by: Q2 2025 Outlook Report April 2025 2 April 2025 Copyright ©️ 2025 Pharma Intelligence UK Limited, a Citeline company (Unauthorized photocopying prohibited) Contents About the Author ............................................................................................................................................ 3 Executive Summary ....................................................................................................................................... 3 Disclaimer ........................................................................................................................................................ 3 Outcomes of Biomedtracker’s Large Impact Drug Catalysts from the Early 2025 Outlook Report ... 4 Drugs ................................................................................................................................................................ 6 VesiGel for Bladder Cancer ..................................................................................................................................... 6 Pixclara for Brain Cancer - Imaging ........................................................................................................................ 7 Reproxalap for Dry Eye (Ophthalmology) .............................................................................................................. 8 EB-101 for Epidermolysis Bullosa ........................................................................................................................... 9 Rinvoq for Giant Cell Arteritis ................................................................................................................................ 10 Sebetralstat for Hereditary Angioedema (HAE) .................................................................................................. 11 SL-1009 for Metabolic - General ........................................................................................................................... 12 Nipocalimab for Myasthenia Gravis (MG) ............................................................................................................ 13 STS101 for Migraine and Other Headaches ....................................................................................................... 14 NVK-002 for Myopic Macular Degeneration (MMD)/Pathological Myopia (Ophthalmology) ....................... 15 Dovbleron for Non-Small Cell Lung Cancer (NSCLC) ....................................................................................... 16 Defactinib for Ovarian Cancer ............................................................................................................................... 17 Clesrovimab for Respiratory Syncytial Virus (RSV) Prevention ........................................................................ 18 Deals.......................................................................................................